Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization

doi:10.3748/wjg.v26.i15.1805

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6257)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

434

WORD

147

HTML

3258

Figures (1-5)

228

Tables (1-4)

167

Sum=4234

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

685

Download

1338

Sum=2023

Apr 21, 2020 (publication date) through May 4, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 21, 2020; 26(15): 1805-1819
Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1805

Table 4 Comparison of the performance and discriminating abilities of the proposed models and six-and-twelve criteria

Prognostic models	AUROC (95%CI)			LR χ²	df	C-index (95%CI)	R²
Prognostic models	1-yr	2-yr	3-yr	LR χ²	df	C-index (95%CI)	R²
Model 1	0.72 (0.68-0.76)	0.69 (0.65-0.74)	0.66 (0.60-0.71)	98.4	3	0.65 (0.63-0.68)	0.117
LP = TS + TN + 2.9 × AFP	0.72 (0.68-0.76)	0.69 (0.65-0.74)	0.66 (0.60-0.71)	98.4	3	0.65 (0.63-0.68)	0.117
Model 2	0.72 (0.68-0.76)	0.69 (0.56-0.73)	0.67 (0.61-0.72)	101.4	4	0.66 (0.64-0.69)	0.120
LP = TS + TN + 3.2 × AFP + 3.8 × ALBI	0.72 (0.68-0.76)	0.69 (0.56-0.73)	0.67 (0.61-0.72)	101.4	4	0.66 (0.64-0.69)	0.120
Model 3	0.74 (0.71-0.78)	0.72 (0.68-0.76)	0.68 (0.63-0.74)	124.3	4	0.67 (0.65-0.70)	0.149
LP = TS + 1.1 × TN + 2.7 × AFP + 0.1 × TBIL	0.74 (0.71-0.78)	0.72 (0.68-0.76)	0.68 (0.63-0.74)	124.3	4	0.67 (0.65-0.70)	0.149
Six-and-twelve criteria	0.74 (0.70-0.77)	0.71 (0.67-0.75)	0.68 (0.63-0.74)	114.3	2	0.67 (0.64-0.69)	0.134
LP = TS + TN	0.74 (0.70-0.77)	0.71 (0.67-0.75)	0.68 (0.63-0.74)	114.3	2	0.67 (0.64-0.69)	0.134

AUROC: Area under receiver operating characteristic curve; LR: Likelihood ratio; LP: Linear predictor; TS: Tumor size; TN: Tumor number; ALBI: Albumin-bilirubin grade; AFP: Alpha-fetoprotein; TBIL: Total bilirubin.

Citation: Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819
URL: https://www.wjgnet.com/1007-9327/full/v26/i15/1805.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i15.1805